{
  "slug": "olio-labs",
  "name": "Olio Labs",
  "yc_id": 29128,
  "batch": "Summer 2023",
  "website": "https://oliolabs.co/",
  "web_data": {
    "web_enrichment_version": "1.0.0",
    "enriched_at": "2025-10-17T01:26:36.124487",
    "website": "https://oliolabs.co/",
    "website_status": {
      "reachable": true,
      "status_code": 200,
      "response_time_ms": 1268.91,
      "final_url": "https://oliolabs.co/",
      "redirected": false,
      "checked_at": "2025-10-17T01:26:37.393404"
    },
    "ssl_security": {
      "disabled": true,
      "reason": "certificate_verification_failed"
    },
    "domain_info": {
      "domain": "oliolabs.co",
      "registrar": "GoDaddy.com, LLC",
      "creation_date": "2023-03-28T20:17:40",
      "expiration_date": "2027-03-28T23:59:59",
      "domain_age_days": 933,
      "domain_age_years": 2.6,
      "name_servers": [
        "NS-1715.AWSDNS-22.CO.UK",
        "NS-427.AWSDNS-53.COM",
        "NS-897.AWSDNS-48.NET",
        "NS-1454.AWSDNS-53.ORG"
      ]
    },
    "social_links": {
      "twitter": null,
      "linkedin": null,
      "github": null,
      "facebook": null,
      "instagram": null,
      "youtube": null
    },
    "security_headers": {
      "strict_transport_security": false,
      "content_security_policy": false,
      "x_frame_options": false,
      "x_content_type_options": false,
      "x_xss_protection": false,
      "referrer_policy": false,
      "security_score": 0,
      "server": "AmazonS3"
    }
  },
  "enrichment_version": "1.0.0",
  "enriched_at": "2025-10-17T10:39:19.453419",
  "phase1_complete": true,
  "phase2_complete": false,
  "phase3_complete": false,
  "phase4_complete": false,
  "phase5_complete": false,
  "ai_insights": {
    "ai_insights_version": "1.0.0",
    "model_used": "claude-sonnet-4-20250514",
    "enriched_at": "2025-10-17T11:40:50.177427",
    "status": "success",
    "market_analysis": {
      "market_size": "very large",
      "market_stage": "growing",
      "key_trends": [
        "AI-driven drug discovery acceleration",
        "Combination therapy preference over single-target drugs",
        "Obesity epidemic driving massive GLP-1 market growth"
      ]
    },
    "competitive_positioning": {
      "competitive_moat": "Proprietary AI platform for multi-protein interaction modeling and combination therapy optimization",
      "differentiation": "AI-powered combination therapeutics targeting thousands of protein interactions vs traditional single-target approaches",
      "competitive_advantages": [
        "Custom ML built from real-world expertise",
        "Ability to search trillions of drug combinations",
        "Focus on reducing side effects while improving efficacy"
      ],
      "competitive_vulnerabilities": [
        "Competing against established pharma giants with deep pockets",
        "Regulatory approval complexity for combination therapies"
      ]
    },
    "business_model": {
      "revenue_model": "Biotech licensing/partnerships",
      "scalability": "high",
      "capital_intensity": "high"
    },
    "growth_assessment": {
      "growth_stage": "seed",
      "growth_indicators": [
        "Targeting fastest-growing drug market (GLP-1s)",
        "AI-first approach in hot biotech sector"
      ],
      "growth_bottlenecks": [
        "Long drug development timelines",
        "Regulatory approval requirements",
        "Need for significant clinical trial funding"
      ]
    },
    "risk_analysis": {
      "market_risk": "medium",
      "technology_risk": "high",
      "execution_risk": "high",
      "overall_risk_score": 8,
      "key_risks": [
        "Clinical trial failure risk",
        "Regulatory approval uncertainty",
        "Competition from Big Pharma with similar AI initiatives"
      ]
    },
    "investment_thesis": {
      "strengths": [
        "Massive addressable market in obesity/diabetes",
        "Novel AI approach to drug discovery",
        "Potential for superior efficacy with fewer side effects"
      ],
      "concerns": [
        "Early stage with unproven clinical results",
        "High capital requirements for drug development",
        "Long path to revenue generation"
      ],
      "exit_potential": "acquisition",
      "comparable_companies": [
        "Recursion Pharmaceuticals",
        "Atomwise",
        "Insitro"
      ]
    },
    "recommendations": {
      "next_steps": [
        "Secure partnerships with established pharma companies",
        "Generate proof-of-concept clinical data"
      ],
      "expansion_opportunities": [
        "Apply AI platform to other disease areas beyond obesity",
        "License platform technology to other biotech companies"
      ]
    },
    "tokens_used": {
      "input": 713,
      "output": 607,
      "total": 1320,
      "estimated_cost": 0.011244
    }
  },
  "phase8_complete": true
}